Daisuke Okajima

USPTO Granted Patents = 11 (Patent Applications = 11)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 49(Granted Patents)

Company Filing History:

11 out of 441

Daiichi Sankyo Company, Limited

patents

3 out of 34

Sapporo Medical University

patents

2 out of 11

Kazusa Dna Research Institute Foundation

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12350344 - Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate (2025-07-08),

2. 12312641 - Sensitivity marker for antibody-drug conjugate (2025-05-27),

3. 12246196 - Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines (2025-03-11),

4. 11628223 - Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines (2023-04-18),

5. 11583590 - Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor (2023-02-21),

6. 11173213 - Method for selectively manufacturing antibody-drug conjugate (2021-11-16),

7. 11008398 - Anti-TROP2 antibody-drug conjugate (2021-05-18),

8. 10227417 - Anti-TROP2 antibody-drug conjugate (2019-03-12),

9. 9850312 - Anti-TROP2 antibody-drug conjugate (2017-12-26),

10. 7977069 - DNA encoding a CCK-8S G-protein coupled receptor, and vectors, transformants, cell kits, and methods employing such DNA (2011-07-12),

11. 7527937 - Assay employing a g-protein coupled receptor that is activated by CCK-8S (2009-05-05),

Title: Daisuke Okajima: Innovator in Cancer Treatment

Introduction

Daisuke Okajima is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer treatment, holding a total of 11 patents. His innovative work focuses on developing novel therapeutic methods that target specific cancer markers.

Latest Patents

Among his latest patents is a method for treating tumors by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate. This invention provides a novel antibody-pyrrolodiazepine derivative and a conjugate that utilizes this derivative, along with a new CLDN6 and/or CLDN9 antibody. Another significant patent involves a sensitivity marker for antibody-drug conjugates. This method identifies patients suitable for treatment with an anti-hTROP2 antibody by evaluating gene expression levels in biological samples from cancer patients.

Career Highlights

Daisuke Okajima has worked with notable organizations such as Daiichi Sankyo Company, Limited and Sapporo Medical University. His experience in these institutions has allowed him to advance his research and contribute to the development of innovative cancer therapies.

Collaborations

He has collaborated with esteemed colleagues, including Hirofumi Hamada and Narihiro Toda, to further enhance his research efforts and drive innovation in the medical field.

Conclusion

Daisuke Okajima's work exemplifies the impact of innovation in cancer treatment. His patents and collaborations reflect a commitment to improving patient outcomes through advanced therapeutic methods.

This text is generated by artificial intelligence and may not be accurate.